Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer

2013 ◽  
Author(s):  
JT Dalton ◽  
R Narayanan ◽  
MS Steiner
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Selective Androgen Receptor Modulators ◽  
Receptor Modulators ◽  
Positive Breast Cancer

Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 568-568 ◽  
Author(s):  
Beth Overmoyer ◽  
Pedro Sanz-Altamira ◽  
Ryan P. Taylor ◽  
Michael L. Hancock ◽  
James T. Dalton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Positive Breast Cancer

scholarly journals Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells

2020 ◽  
Vol 590 ◽  
pp. 119963
Author(s):  
Xiangshang Xu ◽  
Li Li ◽  
Xiaolan Li ◽  
Deding Tao ◽  
Peng Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Positive Breast Cancer

The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer

2021 ◽  
Vol 27 (2) ◽  
pp. 310-320 ◽  
Author(s):  
Theresa E. Hickey ◽  
Luke A. Selth ◽  
Kee Ming Chia ◽  
Geraldine Laven-Law ◽  
Heloisa H. Milioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Tumor Suppressor ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3540
Author(s):  
Hamid Maadi ◽  
Mohammad Hasan Soheilifar ◽  
Won-Shik Choi ◽  
Abdolvahab Moshtaghian ◽  
Zhixiang Wang
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Cancer Patients ◽  
Mechanism Of Action ◽  
Mechanisms Of Action ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Insight Into ◽  
Positive Breast Cancer

Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast cancer patients was introduced in 1998. Although trastuzumab has opened a new avenue to treat patients with HER2-positive breast cancer and other types of cancer, some patients are not responsive or become resistant to this treatment. So far, several mechanisms have been suggested for the mode of action of trastuzumab; however, the findings regarding these mechanisms are controversial. In this review, we aimed to provide a detailed insight into the various mechanisms of action of trastuzumab.

Breast cancer in transgender female‐to‐male individuals: A case report of androgen receptor‐positive breast cancer

2019 ◽  
Vol 26 (5) ◽  
pp. 1007-1012 ◽  
Author(s):  
Adam Fundytus ◽  
Nathalie Saad ◽  
Natalie Logie ◽  
Gloria Roldan Urgoiti
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Androgen Receptor ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document